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mean age at baseline was 54  9; 81 % of the patients are male. The average number
of anti-hypertensive medications at baseline was 5.4. The majority (72%) of patients
were on spironolactone at baseline. 50% of patients had changes to their medications
in response to BP changes during the 6 month follow-up period. Mean ofﬁce SBP was
16718 mmHg and mean ambulatory SBP was 15714 mmHg at baseline. Of re-
sponders, the mean decrease in ofﬁce SBP at 6months was -4125 and the mean
decrease in ambulatory SBP was -2722 at 6 months. At 1 month, MSNA decreased
by 17%; the decrease in MSNA correlated with a decrease in BP 10 mmHg in 4 of
5 patients. The most commonly reported adverse event was procedural-related pain.
There have been no reports of new onset renal artery stenosis.
Conclusions: The REALISE trial demonstrates that blood pressure can be safely
reduced in patients with moderate resistant hypertension. Ultrasound renal denervation
may provide beneﬁt in a subset of patients despite active on-going medical
management.
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24h Ambulatory Blood Pressure (ABPM) Change After Using The New
Symplicity Spyral Renal Sympathetic Denervation Device In Patients With
Resistant Hypertension – First Results From The Halle-RDN-Registry
Alexander Plehn1, Wolf Baeumler1, Alexander Vogt1, Daniel Medenwald1
1Martin Luther University Halle-Wittenberg, Halle, Germany
Background: Despite the widely discussed unfavorable outcome of the Symplici-
tyTM HTN 3 trial, several independent trials and registries have shown a blood
pressure (BP) lowering effect in the majority of patients treated with a renal dener-
vation (RDN) device. So far, current available data are almost entirely based on the
SymplictyTM Flex System, a second-generation RDN device. Although well estab-
lished and approved, it revealed several limitations like high time consumption, high
rigidity and often a more or less random ablation pattern. The next generation Sym-
plicityTM Spyral device has been designed to overcome many of these shortcomings
by using multiple electrodes strung on a helical shaped catheter. However, the
question about the effectiveness of the new system still remains.
Methods: Our study carefully investigated the ABPM response to RDN in a cohort
of 29 consecutively treated patients with resistant hypertension using the Spyral
device. Baseline values included a mean age of 67 9.8 years, BMI of 31.3  4.4
Kg/m2, 48% women, 56% diabetic, 29% coronary artery disease and 5.4 1.2
antihypertensive medications. A 24h BP monitoring was recorded in every patient
24h before as well as 24h and 3 months after RDN. BP readings were then averaged
according to daytime (7:00am-22:00pm), nighttime (22:00pm-7:00am) and 24 hours
intervals. All data were statistically analyzed using mixed models with repeated
measurements.
Results: In treated patients mean averaged systolic 24h BP was reduced by 14.54.6
mm Hg (p< 0.005; n 29) during the ﬁrst 24 hours. A similar effect on diastolic BP was
observed: 4.92.26 mmHg (p< 0.05). First analyses of 17 patients reaching the 3
months follow-up visit reveal a sustained systolic (7.32.39 mm Hg, p< 0.05) as well
as diastolic (4.84.46 mm Hg, p< 0.05) ABPM reduction, without further decrease –
on the contrary a slight relapse to higher BP was seen.
Conclusions: Using the multi-electrode SymplicityTM Spyral renal denervation de-
vice did not only improved steerability, ablation pattern and procedure time. It also
seems to show a signiﬁcant immediate as well as persisting reduction of systolic and
diastolic ABPM.
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Ethanol-Based Renal Sympathetic Denervation: Current Approaches
Tim Fischell1
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Background: Ethanol (EtOH)-induced renal sympathetic denervation (RDN) has
been described. We compare the results of percutaneous vs. endovascular infusion of
EtOH.
Methods: MR-guided injection of 5 or 10 ml of EtOH per renal artery to the peri-
arterial space was performed in pigs, with 4-week renal norepinephrine (NE) and
histopathology data. In the same model, the Peregrine System was used to infuse
0.15, 0.30 or 0.60 ml of EtOH to the peri-vascular space of each renal artery. His-
topathology, NE assay and immunostaining were performed at 2 weeks and 3 months.
In a clinical setting, a CT-guided injection of EtOH (10 ml) was reported, and a safety
and feasibility study (18 patients) is ongoing with the Peregrine System (0.30 ml
EtOH).
Results: In pigs, 5 or 10 ml MR-guided EtOH injections yielded NE reductions of 0%
and 53% vs. controls. The 5 ml EtOH produced no changes in renal nerve histology.
The 10 ml injection resulted in neural degeneration, perineural ﬁbrosis; hydro-
nephrosis and kidney adhesions were observed. By comparison, pigs treated with
micro-doses (endovascular) of EtOH, renal NE, neuroﬁlament protein and tyrosine
hydroxylase were all reduced in a dose-dependent manner, and circumferential
sympathetic nerve injury (2–10 mm depth from intima) was observed at all doses.
Renal NE dropped by 58%, 78% and 88%. No signiﬁcant vascular wall changes or
other systemic or anatomic pathologies were reported. The patient treated with CT-
guided injection of EtOH (10 ml) ofﬁce blood pressure (OBP) and ABPM were
lowered by 29/14 of 15/8, respectively, at 4 weeks, with no adverse anatomical
changes. No adverse events and either no pain or transient pain (< 2 min) were
observed with the Peregrine System using 0.3 ml EtOH (18 patients). At 4 weeks, theJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/HyOBP dropped an average of 27/11, while antihypertensive medications were reduced
from 3.2 to 2.1.
Conclusions: EtOH delivery into the periarterial space appears to be safe and feasible
for RDN. In preclinical testing, micro-volumes delivered via a specialized endovas-
cular catheter enabled a superior treatment than a percutaneous technique. The ob-
servations of minimal pain, safety and early efﬁcacy with this approach in a clinical
setting, are encouraging.TCT-420
Safety and Performance of the Next Generation EnligHTN Renal Denervation
System in Patients with Drug-resistant Hypertension: 12-Month Results From a
First-in-Human Multicenter Study
Stephen G. Worthley1, Mark W. Webster2, Joseph Montarello3, Paul Antonis4,
Robert J. Whitbourn5
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Background: Catheter-based renal artery denervation therapy has become established
as a therapeutic option in patients with resistant hypertension. We further investigated
the safety and performance of the next generation EnligHTN Renal Denervation
System (St. Jude Medical) in patients with drug-resistant hypertension.
Methods: The EnligHTN Renal Artery Ablation Catheter has 4 electrodes attached on
a basket mounted at the tip of the catheter. The next generation EnligHTN RF
Ablation Generator utilizes a novel algorithm for the delivery of 1 minute of radio-
frequency energy, optimized for simultaneous delivery of therapy through all 4
electrodes, with an interactive, intuitive user interface. Renal denervation was per-
formed on 39 patients across 6 centers meeting the following inclusion criteria: 18-80
years of age, a systolic BP 160 mmHg, an average daytime systolic ambulatory BP
135 mmHg, on three or more antihypertensive agents (including a diuretic). Renal
artery CT angiography was repeated at 6 months in all patients.
Results: To date 37/38 patients have completed 6-months of follow-up post proce-
dure. No serious device or procedure related adverse events have been observed as
adjudicated by an independent Clinical Events Committee. There were no clinically
signiﬁcant changes in renal function through 6-months as observed in eGFR, serum
creatinine, cystatin C, or urine albumin-to-creatinine ratio. 6-month ofﬁce (and
24 hour ambulatory) BP reductions from baseline were -25.2/-7.3 (-8.2/-2.0) mmHg,
which were statistically signiﬁcant except for the ambulatory diastolic reduction.
Renal artery denervation procedures were performed successfully in all patients, with
an average of 4.33 ablation sets and 15.85 ablations performed per patient. The mean
total ablation catheter insertion-to-removal time was 22.38 min and mean ablation
time was 4.33 min per patient.
Conclusions: Accumulated 12-month results from all sites will be presented. After
6-months follow-up in this ﬁrst-in-human study, we conclude that data demonstrates
the next generation EnligHTN Renal Denervation System continues to be safe, rapid,
and effective in the treatment of patients with drug-resistant, uncontrolled
hypertension.TCT-421
Renal denervation in hypertensive patients: effects on neurohormonal activation
and cardiac natriuretic peptides
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Background: Renal denervation is a emerging treatment in patients with resistant
arterial hypertension. Neurohromonal activation (catecholaminergic and renin angio-
tensin aldosterone systems) play an important role in hypertensive patients; B-type
cardiac natriuretic peptides have been demonstrated as useful biomarkers of both
neurohormonal activation and cardiovascular overload.
Aim: To investigate effects of renal denervation on biomarkers of neurohormonal
activation and NT-proBNP serum values.
Methods: 6 patients with resistant hypertension (mean value >140/90 mmHg at
24 hours blood pressure monitoring despite use of three or more antihypertensive
medications) underwent renal denervation. Norepineprhine (NE), plasma renin ac-
tivity (PRA), aldosterone (A) and NT-proBNP were collected at baseline (B), 1 day
(1D) and 1 month (1M) after the procedure. Patients underwent 24 hours blood
pressure monitoring at B, 1D and 1M after the procedure. Any change in antihyper-
tensive medications was made after the procedure.
Results: All procedures were performed without complications. Mean age 64  12
years (range 43-75), 5 patients males. Diuretics were used in 6 out of 6 patients.
Systolic (1386 at 1M vs. 1508 at 1D and 1516 mmHg at B, p< 0.01), diastolic
(7310 at 1M vs.7912 at 1D and 8112 mmHg at B, p< 0.01) and mean (946 at
1M vs. 1027 at 1D and 1056 mmHg at B, p< 0.01) arterial pressure values, allpertension Therapies Including Renal Denervation B123
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vs. 353; 178-490 at B, p< 0.01), NE (441; 198-598 at 1M vs. 752; 629-850 at B, p<
0.01) and A (98; 75-128 at 1M vs. 165; 114-269 at B, p< 0.01) all decreased at 1M
after renal denervation procedure, while PRA did not change. Percentual decrease of
mean arterial pressure was strictly correlated with both percentual decrease in NT-
proBNP (r¼ 0.742, p< 0.05) and NE (r¼ 0.924, p< 0.01).
Conclusions: Biomarkers of neurohormonal activation and cardiovascular overload
such as norepinephrine, aldosterone and B-type natriuretic peptides appear positively
affected by renal denervation procedure in resistant hypertensive patients. Interest-
ingly, decrease of such neurohormones strictly reﬂect decrease in arterial pressure
values.
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Transluminal Imaging of Renal Nerves using Optical Coherence Tomography
Fumiaki Ikeno1, David Lambert2, Arjun M. Desai3
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Background: Renal denervation for refractory hypertension has received considerable
interest in recent years. Initial clinical data demonstrated a signiﬁcant reduction in
blood pressure following radiofrequency ablation of the renal nerves. However, the
recent clinical trial SYMPLICITY HTN-3 failed to meet efﬁcacy endpoints. One
theory for insufﬁcient efﬁcacy is incomplete ablation of the renal nerve. In this study
we test if the renal nerves, in particular the main renal nerve bundle, could be visu-
alized through the renal arterial wall using optical coherence tomography (OCT) to
guide more precise ablative energy.
Methods: Specimens included fresh porcine abdominal aortas with kidneys attached.
The Ocelot catheter (Avinger Inc, Redwood City, CA) using a 1300 nm OCT swept
source laser was inserted through the aorta and advanced to the renal artery. Following
OCT imaging, the tissue was ﬁxed, sectioned (5 mm thick), and stained with hema-
toxylin and eosin.
Results: Figure 1 displays an OCT image from within the renal artery juxtaposed with
the identical histologic arterial section. OCT accurately identiﬁes the location of the
renal nerve bundle via the optical properties of the surrounding myelin, which creates
delineated borders when compared with neighboring adventitia.
Conclusions: OCT is gaining increased use within cardiovascular imaging and
therapy. The clear identiﬁcation and localization of the renal nerve bundle via OCT
may prove useful for targeted ablative therapies, including renal denervation.B124 JACC Vol 64/11/Suppl B j September 13–17, 2014TCT-423
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Background: While the efﬁcacy of a ﬁrst generation radio frequency renal dener-
vation device has recently been challenged, new technologies are available designed
to optimize procedural success. The Paradise Renal Denervation System (ReCor
Medical, Palo Alto, CA) delivers ultrasound energy to perform targeted circumfer-
ential denervation of the renal sympathetic nerves in order to reduce blood pressure
(BP) and secondary end-organ damage.
Methods: The ACHIEVE study is a prospective, multi-center, non-randomized,
post-market study to evaluate the clinical outcome of renal denervation with the
Paradise System in patients with resistant hypertension. Major exclusions include
renal artery stenosis and moderate to severe renal insufﬁciency. Patients were
treated with the Paradise system and followed for 12 months. Non-invasive im-
aging using CR or MRI was performed at 12-months to assess renal artery patency.
Safety and efﬁcacy endpoints were evaluated including renal complications,
changes in ofﬁce and ambulatory BP, changes in medication and Quality of Life
measures.
Results: Eight sites in Europe are actively recruiting in the ACHIEVE study.
Mean age at treatment is 6311 years (range 38-86 years) and 56% of patients
are male. At baseline, mean ofﬁce systolic BP is 17720 mmHg (n¼67) and
mean ambulatory systolic BP is 15613 mmHg (n¼62). Early data demonstrate a
signiﬁcant decrease in systolic ofﬁce BP at 30 days post treatment (average BP
change of -16mmHg, n¼47, p< 0.005), sustained at both 3 and 6 months. Pa-
tients with baseline ofﬁce BP 160mmHg had larger overall drops in systolic BP
versus those whose baseline BP was < 160mmHg (-1929mmHg; n¼29; p<
0.005 versus 2.120mmHg, n¼8). Average 24-hour ambulatory blood pressure
changes are also sustained over follow-up with an average decrease of -7mmHg
recorded at both 3 and 6 months post treatment. No procedure related serious
adverse events occurred in the initial follow-up. Updated results will be presented
at the meeting.
Conclusions: Initial ACHIEVE study results demonstrate that the Paradise System is
safe and effective in patients with resistant hypertension. Early data suggests that a
reduction in BP occurs within 30 days and is sustained.
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Unfavourable Anatomy Of Renal Arteries Should Not Be An Exclusion Criteria
For Renal Sympathetic Denervation
Alexander Plehn1, Wolf Baeumler1, Alexander Vogt1
1Martin Luther University Halle-Wittenberg, Halle, Germany
Background: Catheter-based renal sympathetic denervation (RDN) is indicated for
treatment-resistant arterial hypertension (systolic pressure 160 mmHg on 3 anti-
hypertensive drugs). A radiofrequency catheter induces controlled thermal sympa-
thetic nerve destruction in the renal arteries resulting in lowered sympathetic tone and
blood pressure (BP). According to the Symplicity trials, patients with anatomical
abnormalities of the renal arteries like additional arteries or early bifurcations have not
been eligible for this treatment.
Methods: Our study carefully investigated the ambulatory 24 hour blood pressure
(ABPM) response to RDN in a cohort of 181 consecutively treated patients with
resistant hypertension. A 24h BP monitoring was recorded in every patient 24h
before as well as 24h, 3 and 6 months after RDN. According to the renal artery
anatomical ﬁndings, the following 5 groups have been identiﬁed: normal anat-
omy, additional arteries, early bifurcation (segmental bifurcation < 15mm from
the ostium), tortuosity and atherosclerotic plaque. All data were statistically
analysed with repeated measures ANOVA and Greenhouse-Geisser correction if
indicated.
Results: In treated patients (age 63 9.6 years, BMI 31.9 5.8 Kg/m2, 48% women,
48% diabetic, 19% coronary artery disease and 5.7 1.8 antihypertensive medica-
tions) mean averaged systolic 24h BP was signiﬁcantly reduced in every anatomical
group during the ﬁrst 24 hours. Patients with additional renal arteries or early bi-
furcations seem to have a more sustained systolic BP reduction at 3 and 6 months
compared to tortuous renal arteries, evidence of plaque or normal anatomies. Here a
relapse to baseline BP was seen.
Conclusions: Patients with resistant hypertension and unfavourable renal vascular
anatomy seem to beneﬁt at least to an equal extent from RDN as patients with normal
renal arteries. However, our data suggest, that tortuosity and atherosclerotic plaque
may be a negative predictor of BP response, whereas early bifurcations and additional
renal arteries appear to be positive predictors.j TCT Abstracts/Hypertension Therapies Including Renal Denervation
